Clinical Trial Update: A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing meropenem-vaborbactam to piperacillin/tazobactam for hospital-acquired and ventilator-associated bacterial pneumonia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hospital-acquired Bacterial Pneumonia
• Hospital-acquired Pneumonia
• Ventilator-associated Bacterial Pneumonia
• Ventilator-associated Pneumonia

Drugs mentioned

• Meropenem-Vaborbactam (meropenem-vaborbactam)
• Piperacillin/tazobactam (Piperacillin/tazobactam)

Snippet

Sponsor: Melinta Therapeutics, Inc. | Conditions: Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia | Phase 3 | Status: WITHDRAWN